查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153491

全球脊髓性肌肉萎縮症（SMA）治療市場規模、佔有率、趨勢和成長分析報告，2026-2034年

Global Spinal Muscular Atrophy (SMA) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球脊髓性肌肉萎縮症 (SMA) 治療市場預計將從 2025 年的 58.6 億美元成長至 2034 年的 271.8 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 18.58%。 SMA 治療市場正經歷快速成長，這主要得益於基因療法的突破和早期診斷的努力。 SMA 曾被認為是一種致命的兒童疾病，治療選擇有限，但如今，緩解疾病藥物和基因替代療法的出現使患者受益匪淺。新生兒篩檢的普及和早期療育顯著改善了患者的預後，從而推動了市場擴張。

關鍵促進因素包括反義寡核苷酸療法的進步、基因療法的創新以及針對罕見疾病的強力的監管激勵措施。生物技術公司與醫療機構之間的策略獎勵改善了藥物分銷和患者可近性。臨床醫生和患者權益組織的高度重視進一步促進了早期診斷和及時治療。

隨著下一代基因編輯技術和遞送系統的改進，市場預計將進一步發展。長期療效數據和適應症的擴大可望擴大符合治療條件的患者群體。然而，高昂的治療費用和保險報銷方面的挑戰仍然是重要的考慮因素。持續的創新和支持性的醫療政策將塑造未來的成長軌跡。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球脊髓性肌肉萎縮症 (SMA) 治療市場：按類型分類

  • 市場分析、洞察與預測
  • 1型
  • 類型 2
  • 3型
  • 4型

第5章 全球脊髓性肌肉萎縮症 (SMA) 治療市場：依治療方式分類

  • 市場分析、洞察與預測
  • 基因治療
  • 製藥

第6章 全球脊髓性肌肉萎縮症（SMA）治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射

第7章 全球脊髓性肌肉萎縮症（SMA）治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Biogen
    • Roche
    • Novartis
    • Scholar Rock
    • Ionis Pharmaceuticals
    • PTC Therapeutics
    • Astellas Pharma
    • Solid Biosciences
    • Regeneron
    • Cytokinetics
    • Sarepta Therapeutics
    • BioMarin
    • AveXis/Novartis
    • Genentech/Roche
    • Ionis/Biogen
    • Dynacure
    • FibroGen
    • Capricor Therapeutics
    • Sarepta
    • Scholar Rock
簡介目錄
Product Code: VMR11210467

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 27.18 Billion in 2034 from USD 5.86 Billion in 2025, growing at a CAGR of 18.58% during 2026-2034.The spinal muscular atrophy (SMA) treatment market has grown rapidly due to breakthroughs in genetic therapies and early diagnosis initiatives. Previously considered a fatal pediatric disorder with limited options, SMA now benefits from disease-modifying drugs and gene replacement therapies. Increased newborn screening and earlier intervention have significantly improved patient outcomes, driving market expansion.

Key drivers include advancements in antisense oligonucleotide therapies, gene therapy innovations, and strong regulatory incentives for rare diseases. Strategic collaborations between biotech firms and healthcare providers have enhanced distribution and patient access. High awareness among clinicians and patient advocacy groups has further supported early diagnosis and timely treatment initiation.

Looking ahead, the market is expected to evolve with next-generation gene-editing approaches and improved delivery systems. Long-term efficacy data and expanded indications may broaden patient eligibility. Nevertheless, high therapy costs and reimbursement challenges remain significant considerations. Continued innovation and supportive healthcare policies will shape future growth trajectories.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Type 1
  • Type 2
  • Type 3
  • Type 4

By Treatment

  • Gene Therapy
  • Drug

By Route of Administration

  • Oral
  • Injection

COMPANIES PROFILED

  • Biogen, Roche, Novartis, Scholar Rock, Ionis Pharmaceuticals, PTC Therapeutics, Astellas Pharma, Solid Biosciences, Regeneron, Cytokinetics, Sarepta Therapeutics, BioMarin, AveXis/Novartis, Genentech/Roche, Ionis/Biogen, Dynacure, FibroGen, Capricor Therapeutics, Sarepta, Scholar Rock

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Type 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Type 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Type 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Type 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment
  • 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Treatment
    • 7.2.3 By Route Of Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Treatment
    • 7.3.3 By Route Of Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Treatment
    • 7.4.3 By Route Of Administration
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Treatment
    • 7.5.3 By Route Of Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Treatment
    • 7.6.3 By Route Of Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Biogen
    • 9.2.2 Roche
    • 9.2.3 Novartis
    • 9.2.4 Scholar Rock
    • 9.2.5 Ionis Pharmaceuticals
    • 9.2.6 PTC Therapeutics
    • 9.2.7 Astellas Pharma
    • 9.2.8 Solid Biosciences
    • 9.2.9 Regeneron
    • 9.2.10 Cytokinetics
    • 9.2.11 Sarepta Therapeutics
    • 9.2.12 BioMarin
    • 9.2.13 AveXis/Novartis
    • 9.2.14 Genentech/Roche
    • 9.2.15 Ionis/Biogen
    • 9.2.16 Dynacure
    • 9.2.17 FibroGen
    • 9.2.18 Capricor Therapeutics
    • 9.2.19 Sarepta
    • 9.2.20 Scholar Rock